

Appointment of Noel Donnelly as Non-Executive Director

Sydney, Australia – 2 October 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Noel Donnelly as a Non-Executive Director effective 1 October 2024.

Mr Donnelly brings over 25 years of leadership experience in finance, strategy, and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance, and executing complex financial strategies that support rapid company growth.

Currently serving as Chief Financial Officer at PepGen Inc., Mr Donnelly oversaw the company's financial strategy as it undertook a successful Initial Public Offering (IPO) in 2022, raising US\$120M, and leading subsequent financing efforts that secured an additional US\$90M. His leadership was pivotal as PepGen advanced two clinical assets into Phase 1 and 2 trials.

Before joining PepGen, Mr Donnelly was CFO at EIP Pharma (now CervoMed), where he led the company's IPO planning phase. His career also includes a 15-year tenure at Takeda/Shire PLC, where he held various senior roles, including Vice President of R&D Business Operations. At Shire, Mr Donnelly led critical R&D integrations, overseeing more than US\$160 billion in integration planning and execution, and was instrumental in shaping the company's portfolio management strategy, helping prioritise key development assets.

In addition to his operational expertise, Mr Donnelly is highly experienced in business partnering, valuation, investor relations, and decision support analysis, making him a trusted advisor to both executive leadership teams and boards of directors.

Mr Donnelly holds an MBA from the F. W. Olin Graduate School of Business at Babson College and a Bachelor of Science in Nuclear Engineering from the University of Massachusetts, Lowell.

Paul Hopper, Chairman of Radiopharm Theranostics, commented:

"We are lucky to welcome Noel to the board. His extensive experience in finance, operations, and governance, particularly in high-growth environments, will be invaluable as Radiopharm continues to execute its strategy of building a world-class radiopharmaceutical platform. Noel's deep understanding of financial management, combined with his experience in advancing clinical-stage programs, makes him a key addition as we push forward with our pipeline development and strive to deliver value to shareholders."

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical

ASX ANNOUNCEMENT
2 October 2024



stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

InvestorHub – <https://investorhub.radiopharmtheranostics.com/>